Cite
MLA Citation
Tanya Dorff et al.. “340 Phase 1 study of AMG 160, a half-life extended BiTE® (bispecific T-cell engager) therapy targeting prostate-specific membrane antigen, in patients with metastatic castration-resistant prostate cancer.” Journal for immunotherapy of cancer, vol. 8, n.d., pp. A207–A208. http://access.bl.uk/ark:/81055/vdc_100144716659.0x000003